With promising clinical trials currently in progress, several key considerations should be addressed for future clinical translation: (1) Patient stratification: Presently, YAP/TAZ-targeting therapy finds utmost relevance in tumors carrying NF2 mutations, such as mesothelioma, primarily because these mutations lead to YAP/TAZ hyperactivation. Here, NF2 is linked to mesothelioma.